FXS Patients’ Social Deficits are Linked to Social Anxiety, Eye-tracking Study Says

February 4, 2019

Dr. Craig Erickson and colleagues at the University of Cincinnati used eye-tracking technology to understand sociability in Fragile X syndrome. This study affirms what so many parents, caretakers, and educators suspect: people with fragile X want to be social, and it is anxiety – not lack of interest – which usually hold them back. If anxiety could be reduced, more sociability would likely follow. Dr. Erickson is a Fragile X expert and FRAXA investigator who is currently conducting a Fragile X clinical trial of an investigational new drug.

Read More »
Fragile X Conference

FRAXA Funded Researchers Present at MA Fragile X Conference

April 9, 2018

Boston Children’s Hospital hosted a Fragile X conference with FRAXA-funded researchers Dr. Craig Erickson & Dr. Carol Wilkinson presenting.

Read More »

Takeaways from Fragile X Advocacy Day

March 29, 2018

At my first Fragile X Advocacy Day, I met with Congress and families, advocating together for research and hope.

Read More »
Craig Erickson, MD, Cincinnati Children's Hospital

Fragile X Clinical Trial of AZD7325 in Adults

February 1, 2018

FRAXA funded a trial of AZD7325, a drug that boosts GABA(A), in adults with Fragile X. Led by Dr. Craig Erickson, it also tested innovative biomarkers for future trials.

Read More »
Craig Erickson lab

Brain Imbalance Target of Dr. Erickson’s New Clinical Trial

October 25, 2017

According to Dr. Erickson, AZD7325 is a drug that selectively boosts GABA neurotransmission in the brain. GABA is the primary neurochemical in the brain that blocks brain activation. GABA activity is in balance in the brain with Glutamate activity, which is the primary neurochemical that causes brain activation. In Fragile X, GABA activity is insufficient and glutamate activity is excessive, likely causing brain activity to be out of balance. AZD7325 attempts to correct parts of this imbalance by boosting the insufficient GABA activity in the brains of people with Fragile X.

Read More »
Tori Shaeffer

Development of a Novel GABA-A Agonist in Fragile X Syndrome

September 9, 2013

FRAXA funded analysis of a selective GABA-A drug for Fragile X, leading to a clinical trial at Cincinnati Children’s to test this potential treatment.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (38)